KYTHERA Biopharmaceuticals, Inc. has named F. Michael (Mike) Ball, Chief Executive Officer (CEO) of Hospira, Inc. to its Board of Directors. Mr. Ball brings more than 25 years of healthcare experience to KYTHERA.
Mr. Ball was appointed CEO and director of Hospira, a $4 billion company and the world's leading provider of injectable drugs and infusion technologies, in March 2011. Prior to Hospira, Mr. Ball had a distinguished 16-year career with Allergan, Inc., where he had served as its President from 2006 and previously held a number of leadership roles including executive Vice President and President, Pharmaceuticals; President, North America Region and President, Global Eyecare. During his tenure at Allergan, Mr. Ball led the commercial organization that launched industry-changing products such as Restasis(R) in Opthalmology and BOTOX(R) in neurology and aesthetics. He also led the strategy and execution of global commercial activities for a diverse slate of businesses, including specialty pharmaceuticals, ophthalmology, aesthetics, over-the-counter products and surgical devices.
Before Allergan, Mr. Ball served as Senior Vice President for Syntex Laboratories USA and President, Syntex Canada. He started his healthcare career at Eli Lilly and Company.